Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989968794> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2989968794 endingPage "156" @default.
- W2989968794 startingPage "153" @default.
- W2989968794 abstract "Background/objectives: To evaluate the safety and efficacy of aflibercept in eyes with persistent diabetic macular edema (DME) after treatment with bevacizumab and/or ranibizumab.Subjects/methods: Open-label, prospective study of intravitreal aflibercept injection in eyes with persistent DME after chronic, recent, and frequent bevacizumab and/or ranibizumab.Results: Thirty eyes were enrolled. Mean change in best corrected visual acuity (BCVA) from baseline to 52 weeks was +7 letters. The mean change in optical coherence tomography (OCT) central subfield thickness (CST) from baseline to 52 weeks was -118 um. At week 52, 70% of eyes with a baseline CST>350 um demonstrated>15% reduction in OCT CST. Forty-eight percent of eyes demonstrated no OCT evidence for DME at last visit. OCT-angiography demonstrated vascular density improvement in the deep capillary plexus. No significant ocular adverse events were observed.Conclusion: Aflibercept demonstrated beneficial visual and anatomic outcomes in patients with persistent DME following bevacizumab and/or ranibizumab." @default.
- W2989968794 created "2019-12-05" @default.
- W2989968794 creator A5006636639 @default.
- W2989968794 creator A5025402124 @default.
- W2989968794 creator A5027561282 @default.
- W2989968794 creator A5030155459 @default.
- W2989968794 creator A5035292621 @default.
- W2989968794 creator A5035714910 @default.
- W2989968794 creator A5037351289 @default.
- W2989968794 creator A5050387051 @default.
- W2989968794 creator A5082261567 @default.
- W2989968794 creator A5082988191 @default.
- W2989968794 creator A5090528388 @default.
- W2989968794 date "2019-01-01" @default.
- W2989968794 modified "2023-09-27" @default.
- W2989968794 title "Optical coherence tomography angiographic, visual acuity and anatomic outcomes with aflibercept for diabetic macular edema after bevacizumab and/or ranibizumab." @default.
- W2989968794 hasPublicationYear "2019" @default.
- W2989968794 type Work @default.
- W2989968794 sameAs 2989968794 @default.
- W2989968794 citedByCount "0" @default.
- W2989968794 crossrefType "journal-article" @default.
- W2989968794 hasAuthorship W2989968794A5006636639 @default.
- W2989968794 hasAuthorship W2989968794A5025402124 @default.
- W2989968794 hasAuthorship W2989968794A5027561282 @default.
- W2989968794 hasAuthorship W2989968794A5030155459 @default.
- W2989968794 hasAuthorship W2989968794A5035292621 @default.
- W2989968794 hasAuthorship W2989968794A5035714910 @default.
- W2989968794 hasAuthorship W2989968794A5037351289 @default.
- W2989968794 hasAuthorship W2989968794A5050387051 @default.
- W2989968794 hasAuthorship W2989968794A5082261567 @default.
- W2989968794 hasAuthorship W2989968794A5082988191 @default.
- W2989968794 hasAuthorship W2989968794A5090528388 @default.
- W2989968794 hasConcept C118487528 @default.
- W2989968794 hasConcept C134018914 @default.
- W2989968794 hasConcept C141071460 @default.
- W2989968794 hasConcept C2776694085 @default.
- W2989968794 hasConcept C2777802072 @default.
- W2989968794 hasConcept C2778257484 @default.
- W2989968794 hasConcept C2778749236 @default.
- W2989968794 hasConcept C2778818243 @default.
- W2989968794 hasConcept C2779829184 @default.
- W2989968794 hasConcept C2780347916 @default.
- W2989968794 hasConcept C2781100027 @default.
- W2989968794 hasConcept C2985127711 @default.
- W2989968794 hasConcept C555293320 @default.
- W2989968794 hasConcept C71924100 @default.
- W2989968794 hasConceptScore W2989968794C118487528 @default.
- W2989968794 hasConceptScore W2989968794C134018914 @default.
- W2989968794 hasConceptScore W2989968794C141071460 @default.
- W2989968794 hasConceptScore W2989968794C2776694085 @default.
- W2989968794 hasConceptScore W2989968794C2777802072 @default.
- W2989968794 hasConceptScore W2989968794C2778257484 @default.
- W2989968794 hasConceptScore W2989968794C2778749236 @default.
- W2989968794 hasConceptScore W2989968794C2778818243 @default.
- W2989968794 hasConceptScore W2989968794C2779829184 @default.
- W2989968794 hasConceptScore W2989968794C2780347916 @default.
- W2989968794 hasConceptScore W2989968794C2781100027 @default.
- W2989968794 hasConceptScore W2989968794C2985127711 @default.
- W2989968794 hasConceptScore W2989968794C555293320 @default.
- W2989968794 hasConceptScore W2989968794C71924100 @default.
- W2989968794 hasIssue "2" @default.
- W2989968794 hasLocation W29899687941 @default.
- W2989968794 hasOpenAccess W2989968794 @default.
- W2989968794 hasPrimaryLocation W29899687941 @default.
- W2989968794 hasRelatedWork W1991409385 @default.
- W2989968794 hasRelatedWork W2066605134 @default.
- W2989968794 hasRelatedWork W2070924647 @default.
- W2989968794 hasRelatedWork W2087604601 @default.
- W2989968794 hasRelatedWork W2123096760 @default.
- W2989968794 hasRelatedWork W2253284780 @default.
- W2989968794 hasRelatedWork W2531729507 @default.
- W2989968794 hasRelatedWork W2590420971 @default.
- W2989968794 hasRelatedWork W2600874963 @default.
- W2989968794 hasRelatedWork W2765838647 @default.
- W2989968794 hasRelatedWork W2971306116 @default.
- W2989968794 hasRelatedWork W2972355296 @default.
- W2989968794 hasRelatedWork W2990901999 @default.
- W2989968794 hasRelatedWork W2994341921 @default.
- W2989968794 hasRelatedWork W3008523941 @default.
- W2989968794 hasRelatedWork W3048591097 @default.
- W2989968794 hasRelatedWork W3160253846 @default.
- W2989968794 hasRelatedWork W3179839195 @default.
- W2989968794 hasRelatedWork W3200955316 @default.
- W2989968794 hasRelatedWork W543922 @default.
- W2989968794 hasVolume "3" @default.
- W2989968794 isParatext "false" @default.
- W2989968794 isRetracted "false" @default.
- W2989968794 magId "2989968794" @default.
- W2989968794 workType "article" @default.